Home/Pipeline/MF-300

MF-300

Sarcopenia

Phase 2bActive

Key Facts

Indication

Sarcopenia

Phase

Phase 2b

Status

Active

Company

Epirium Bio

About Epirium Bio

Epirium Bio is a private, clinical-stage biotech founded in 2008, focused on a novel platform targeting mitochondrial biogenesis and function via PGE-2 signaling. The company's most advanced asset, MF-300, is in Phase 2b for sarcopenia, with earlier-stage programs exploring indications like Becker muscular dystrophy, spinal muscular atrophy, and idiopathic pulmonary fibrosis. Led by CEO Russell J. Cox and backed by an $85M Series A, Epirium is advancing its pipeline of oral therapies for diseases with significant unmet need.

View full company profile

Therapeutic Areas

Neuromuscular Diseases Fibrotic Diseases Inflammatory Diseases Muscle Wasting

Other Sarcopenia Drugs

Drug	Company	Phase	Status
BIO101 (20-hydroxyecdysone)	Biophytis	Phase 3	Preparing for Phase 3 trial; Phase 2 completed with positive mobility data.
DT-201	Dystrogen Therapeutics	Preclinical	Research/Discovery
Sarcopenia Drug Combination	Centenara Labs	Discovery	Lead shows potential in models